Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | JAK2 rearrange |
Gene Variant Detail | |
Relevant Treatment Approaches | JAK Inhibitor (Pan) - ATP competitive JAK2 Inhibitor - ATP competitive |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
JAK2 rearrange | myeloid neoplasm | sensitive | JAK2 Inhibitor - ATP competitive | Ruxolitinib | Guideline | Actionable | Jakafi (ruxolitinib) is included in guidelines for patients with a myeloid/lymphoid neoplasm with eosinophilia harboring a JAK2 rearrangement (NCCN.org). | detail... |
JAK2 rearrange | myeloid neoplasm | sensitive | JAK2 Inhibitor - ATP competitive | Fedratinib | Guideline | Actionable | Inrebic (fendratinib) is included in guidelines for patients with a myeloid/lymphoid neoplasm with eosinophilia harboring a JAK2 rearrangement (NCCN.org). | detail... |
JAK2 rearrange | childhood B-cell acute lymphoblastic leukemia | not applicable | N/A | Guideline | Prognostic | JAK2 rearrangements are associated with a poor prognosis in pediatric patients with B-cell acute lymphoblastic leukemia (NCCN.org). | detail... | |
JAK2 rearrange | B-cell acute lymphoblastic leukemia | not applicable | N/A | Guideline | Prognostic | JAK2 rearrangements are associated with a poor prognosis in patients with B-cell acute lymphoblastic leukemia (NCCN.org). | detail... |